Browsing Medicine Research by Publisher "Taylor and Francis Ltd"
Now showing items 1-8 of 8
-
Flight Versus Ground Out-of-hospital Rapid Sequence Intubation Success: a Systematic Review and Meta-analysis
( Taylor and Francis Ltd , 2018 , Article)Introduction: Endotracheal intubation (ETI) is a critical procedure performed by both air medical and ground based emergency medical services (EMS). Previous work has suggested that ETI success rates are greater for air ... -
In honour of Professor Jackie Ying, recipient of the Journal of Drug Targeting's Lifetime Achievement Award�for 2020
( Taylor and Francis Ltd , 2020 , Article)[No abstract available] -
In honour of Professor Leaf Huang, recipient of the Journal of Drug Targeting's life-time achievement award for 2018
( Taylor and Francis Ltd , 2018 , Article)[No abstract available] -
In honour of Professor Patrick Couvreur, recipient of the Journal Of Drug Targeting?s Lifetime Achievement Award For 2019
( Taylor and Francis Ltd , 2019 , Article)[No abstract available] -
In honour of Professor Patrick Couvreur, recipient of the Journal Of Drug Targeting’s Lifetime Achievement Award For 2019
( Taylor and Francis Ltd , 2019 , Other)[No abstract available] -
In honour of Professor Ruth Duncan, recipient of the Journal of Drug Targeting's Lifetime Achievement Award for 2017
( Taylor and Francis Ltd , 2017 , Other)[No abstract available] -
Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
( Taylor and Francis Ltd , 2020 , Article)Objectives: Recent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize ... -
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
( Taylor and Francis Ltd , 2020 , Article Review)The COVID-19 pandemic is caused by the severe acute-respiratory-syndrome-coronavirus-2 that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE inhibitors (ACEIs) and angiotensin-II receptor ...